Cutaneous Gamma-Delta T-Cell Lymphoma Successfully Treated With Brentuximab Vedotin

an ongoing partial response (Figure, B). However, tumor biopsies were declined by the patient. Furthermore, the creatinine level remained stable at 5.25 mg/dL. Vismodegib treatment was tolerated without any clinically relevant adverse effects. Interestingly, the common adverse effects such as muscle cramps of thelowerleg,fatigue,weightloss,ordysgeusiawerenotreported. Only alopecia developed within the first 4 weeks of treatment. The patient‘s quality of life was significantly improved by reepithelialization of ulcerated and bleeding areas of the tumor. In particular, the formation of an epiphysis of the right midface contributed to an improvement of the patient’s quality of life. At last follow-up, treatment with vismodegib was being continued at the same dose.